Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice

  • Authors:
    • Hitoshi Yoshiji
    • Ryuichi Noguchi
    • Shigeki Kuriyama
    • Junichi Yoshii
    • Yasuhide Ikenaka
  • View Affiliations

  • Published online on: March 1, 2005     https://doi.org/10.3892/or.13.3.491
  • Pages: 491-495
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Angiogenesis is now recognized as playing a pivotal role in hepatocarcinogenesis. The aim of our current study was to examine the combination effect of the clinically used interferon-β (IFN) and angiotensin-converting enzyme inhibitor, perindopril (PE), on hepatocarcinogenesis induced by diethylnitrosamine, especially in conjunction with angiogenesis. Single treatment with either IFN or PE significantly attenuated the development of hepatocellular carcinoma (HCC), and the combination of IFN and PE nearly abolished hepatocarcinogenesis. Both IFN and PE also significantly suppressed the neovascularization and expression of the vascular endothelial growth factor (VEGF), a potent angiogenic factor, in the tumor. These inhibitory effects were similar in magnitude to their inhibitory effects against hepatocarcinogenesis. The combined treatment with IFN and PE resulted in a marked increase of apoptosis in the tumor, whereas tumor cell proliferation was not altered. These results suggested that the combination treatment with IFN and PE may be an effective new strategy for chemoprevention against HCC.

Related Articles

Journal Cover

March 2005
Volume 13 Issue 3

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Yoshiji H, Noguchi R, Kuriyama S, Yoshii J and Ikenaka Y: Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. Oncol Rep 13: 491-495, 2005.
APA
Yoshiji, H., Noguchi, R., Kuriyama, S., Yoshii, J., & Ikenaka, Y. (2005). Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice. Oncology Reports, 13, 491-495. https://doi.org/10.3892/or.13.3.491
MLA
Yoshiji, H., Noguchi, R., Kuriyama, S., Yoshii, J., Ikenaka, Y."Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice". Oncology Reports 13.3 (2005): 491-495.
Chicago
Yoshiji, H., Noguchi, R., Kuriyama, S., Yoshii, J., Ikenaka, Y."Combination of interferon and angiotensin-converting enzyme inhibitor, perindopril, suppresses liver carcinogenesis and angiogenesis in mice". Oncology Reports 13, no. 3 (2005): 491-495. https://doi.org/10.3892/or.13.3.491